drugset / Trial / NCT01946984

Diclofenac vs. Placebo in a Randomized Double Blind Controlled Trial in Post ERCP Pancreatitis

NCT01946984

Phase 1 Completed 182 enrolled Specialized Arab Hospital
RandomizedParallel-groupTriple-blindPrevention

Summary

1. The most common complication of endoscopic retrograde cholangio-pancreaticography (ERCP) is pancreatitis. 2. Several studies showed that non-steroidal anti-inflammatory drugs (NSAIDs) can prevent the post ERCP pancreatitis, the investigators used diclofenac vs placebo. 3. The effect of diclofenac in prevention of that complication, was measured by the number of patients who developed pancreatitis, and compare it with the placebo. 4. The investigators collected 199 patients, 17 excluded, 182 completed the study, all of them underwent the intervention called "ERCP", and randomized to have either Diclofenac or Placebo before the procedure.

Timeline

Start
2012-06
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diclofenac Other / unclassified 75 mg Intramuscular

Indications